Related references
Note: Only part of the references are listed.The miR-200 family and the miR-183 ∼ 96 ∼ 182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers
S. T. Kundu et al.
ONCOGENE (2016)
ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Takeshi Yoshida et al.
PLOS ONE (2016)
ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Xiaoling Song et al.
CANCER RESEARCH (2015)
LAMC2 enhances the metastatic potential of lung adenocarcinoma
Y. W. Moon et al.
CELL DEATH AND DIFFERENTIATION (2015)
Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy
Daniel L. Abravanel et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
Xiaofeng Zheng et al.
NATURE (2015)
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance
Kari R. Fischer et al.
NATURE (2015)
Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers
Jin Sung Jang et al.
SCIENTIFIC REPORTS (2015)
Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers
Zhifu Sun et al.
BMC MEDICAL GENOMICS (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling
Panagiotis Ntziachristos et al.
CANCER CELL (2014)
ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism
Yanan Yang et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis
Xiaoying Wang et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2014)
Inhibition of TBK1 attenuates radiation-induced epithelial-mesenchymal transition of A549 human lung cancer cells via activation of GSK-3β and repression of ZEB1
Wen Liu et al.
LABORATORY INVESTIGATION (2014)
ZEB1 knockdown mediated using polypeptide cationic micelles inhibits metastasis and effects sensitization to a chemotherapeutic drug for cancer therapy
Shengtao Fang et al.
NANOSCALE (2014)
ASPP2 controls epithelial plasticity and inhibits metastasis through β-catenin-dependent regulation of ZEB1
Yihua Wang et al.
NATURE CELL BIOLOGY (2014)
Acquired resistance to TKIs in solid tumours: learning from lung cancer
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
The ErbB/HER family of protein-tyrosine kinases and cancer
Robert Roskoski
PHARMACOLOGICAL RESEARCH (2014)
Different thresholds of ZEB1 are required for Ras-mediated tumour initiation and metastasis
Yongqing Liu et al.
NATURE COMMUNICATIONS (2014)
Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression
Limo Chen et al.
NATURE COMMUNICATIONS (2014)
Molecular mechanisms of resistance in epidermal growth factor receptor-mutant lung adenocarcinomas
Alexis B. Cortot et al.
EUROPEAN RESPIRATORY REVIEW (2014)
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors
Fariz Nurwidya et al.
RESPIRATORY INVESTIGATION (2014)
Acquired Resistance to EGFR Inhibitors Is Associated with a Manifestation of Stem Cell-like Properties in Cancer Cells
Kazuhiko Shien et al.
CANCER RESEARCH (2013)
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo
Mian Xie et al.
EUROPEAN JOURNAL OF CANCER (2013)
KRAS Mutation: Should We Test for It, and Does It Matter?
Patrick J. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
The epigenetics of epithelial-mesenchymal plasticity in cancer
Wai Leong Tam et al.
NATURE MEDICINE (2013)
Loss of E-cadherin activates EGFR-MEK/ERK signaling, which promotes invasion via the ZEB1/MMP2 axis in non-small cell lung cancer
Gab-Yong Bae et al.
ONCOTARGET (2013)
NKX2-1/TITF1/TTF-1-Induced ROR1 Is Required to Sustain EGFR Survival Signaling in Lung Adenocarcinoma
Tomoya Yamaguchi et al.
CANCER CELL (2012)
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
Young-Ho Ahn et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1
Kadoaki Ohashi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells
Diana M. Vallejo et al.
EMBO JOURNAL (2011)
The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells
Simone Brabletz et al.
EMBO JOURNAL (2011)
Epithelial-Mesenchymal Transitions in Development and Disease
Jean Paul Thiery et al.
CELL (2009)
The role of the ZEB family of transcription factors in development and disease
C. Vandewalle et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression
Don L. Gibbons et al.
GENES & DEVELOPMENT (2009)
The basics of epithelial-mesenchymal transition
Raghu Kalluri et al.
JOURNAL OF CLINICAL INVESTIGATION (2009)
A double-negative feedback loop between ZEB1-SIP1 and the microRNA-200 family regulates epithelial-mesenchymal transition
Cameron P. Bracken et al.
CANCER RESEARCH (2008)
A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells
Ulrike Burk et al.
EMBO REPORTS (2008)
Snail, ZEB and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
Hector Peinado et al.
NATURE REVIEWS CANCER (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors
Jeffrey A. Engelman et al.
CLINICAL CANCER RESEARCH (2006)
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features
IYS Tam et al.
CLINICAL CANCER RESEARCH (2006)
Target selectivity of vertebrate notch proteins - Collaboration between discrete domains and CSL-binding site architecture determines activation probability
CT Ong et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition
S Thomson et al.
CANCER RESEARCH (2005)
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: Current knowledge and future directions
W Pao et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
Dominant negative interference of transcription factor AP-2 causes inhibition of ErbB-3 expression and suppresses malignant cell growth
CH Zhu et al.
BREAST CANCER RESEARCH AND TREATMENT (2002)
Tob-mediated cross-talk between MARCKS phosphorylation and ErbB-2 activation
SJ Cho et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Share Paper
